In my role, I lead AstraZeneca’s new Haematology R&D unit, 职责从早期发现到目标识别, to first-in-human clinical studies, to late stage trials and drug approvals.

我是一名临床医生兼科学家，花了超过25年的时间照顾淋巴瘤患者. Prior to joining AstraZeneca, 我在纪念斯隆凯特琳癌症中心(MSKCC)担任淋巴瘤服务部主任, 除了领导一个专注于淋巴细胞恶性肿瘤患者药物开发的实验室. 澳门第一赌城在线娱乐的实验室专注于加速将科学发现转化为新的治疗策略，以提高霍奇金淋巴瘤(HL)和非霍奇金淋巴瘤(NHL)患者的治愈率和生存率. Prior to MSKCC, 我在德克萨斯大学MD安德森癌症中心(MDACC)工作了20年，在那里我指导淋巴瘤和骨髓瘤部门的临床和转化研究.

 

During my tenure in academia, 我领导了许多临床试验，推动了这一领域的发展，并在美国取得了成功.S. 美国食品和药物管理局批准两种治疗霍奇金淋巴瘤的新药, 包括30多年来首个治疗霍奇金淋巴瘤的靶向药物, 以及首个治疗淋巴瘤的免疫检查点抑制剂获批. During the same time, 澳门第一赌城在线娱乐的团队在MDACC和MSKCC方面的努力导致11个新的适应症被批准用于治疗不同类型的淋巴细胞恶性肿瘤患者.

I have published more than 300 papers in peer-reviewed journals, 担任60多项临床试验的首席研究员, including national and international multi-centre studies, 并领导了两个独立的国家癌症研究所资助的MDACC和MSKCC卓越研究专业项目，专注于淋巴瘤患者的新药开发. I also led a Leukemia & 淋巴瘤协会赞助的专门研究中心项目专注于开发第二代 CAR (chimeric antigen receptor) T-cell therapy for patients with blood cancers. 我是淋巴瘤研究基金会科学顾问委员会的前任成员.

After earning a medical degree from the Damascus University School of Medicine in Syria, 我在俄亥俄州托莱多大学的医学和生命科学学院完成了病理学的住院医师实习, in internal medicine at SUNY Downstate College of Medicine, in New York, and a fellowship in haematology/oncology at MSKCC.

 

在过去的二十年里，澳门第一赌城在线娱乐在治疗血癌方面取得了很大的进展, and are entering an exciting new phase of research. As a clinician, 我看到了澳门第一赌城在线娱乐的进步对血癌患者生活的影响. 我很自豪能够将我作为研究人员和血液病学家的背景带到澳门在线赌城娱乐科学界，开发新一代药物，改变血癌患者的生活.

Anas Younes 高级副总裁，血液学(早期和晚期)肿瘤学全球主管&D

CURRENT ROLE

高级副总裁，血液学(早期和晚期)肿瘤学全球主管&D

2013-2019

曾担任纪念斯隆凯特琳癌症中心淋巴瘤服务部主任, 他是医学研究主任的特别顾问. Greenberg Chair in Lymphoma Research from 2019-2020

1992-2013

MD Anderson Cancer Center, served as Professor of Medicine and for almost a decade, 担任淋巴瘤和骨髓瘤部门临床和转化研究主任

2013

Awarded Hodgkin Lymphoma Award, Cologne, Germany

Featured publications

Emerging epigenetic-modulating therapies in lymphoma

Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A. Nat Rev Clin Oncol. 2019 Aug;16(8):494-507. http://www.nature.com/articles/s41571-019-0190-8

伊鲁替尼联合纳武单抗治疗复发性非霍奇金淋巴瘤或慢性淋巴细胞白血病的安全性和活性:1/2a期研究

Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigón MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yağci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W. Lancet Haematol. 2019 Feb;6(2):e67-e78. http://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30217-5/fulltext

 

Brentuximab Vedotin联合化疗治疗III期或IV期霍奇金淋巴瘤

Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. N Engl J Med. 2018 Jan 25;378(4):331-344. http://www.nejm.org/doi/10.1056/NEJMoa1708984

国际工作组共识淋巴瘤反应评价标准(RECIL 2017)

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. Ann Oncol. 2017 Jul 1;28(7):1436-1447. http://www.annalsofoncology.org/article/S0923-7534(19)32246-X/fulltext

 

解释和报告癌症序列变异的标准和指南:分子病理学协会的联合共识推荐, American Society of Clinical Oncology, and College of American Pathologists

Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN.J Mol Diagn. 2017 Jan;19(1):4-23. http://www.jmdjournal.org/article/S1525-1578(16)30223-9/fulltext

brentuximab vedotin治疗复发或难治性霍奇金淋巴瘤患者的5年生存率和持久性结果

Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A. Blood. 2016 Sep 22;128(12):1562-6. http://ashpublications.org/blood/article/128/12/1562/73112/Five-year-survival-and-durability-results-of

 

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, 复发或难治性淋巴瘤或多发性骨髓瘤患者:开放标签, dose-escalation, phase 1 trial

Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano JF, Neelapu SS, Kelly KR, Copeland AR, Akins A, Clancy MS, Gong L, Wang J, Ma A, Viner JL, Oki Y. Lancet Oncol. 2016 May;17(5):622-31. http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00584-7/fulltext

 

自体干细胞移植和brentuximab vedotin失败后，Nivolumab治疗经典霍奇金淋巴瘤:多中心研究, multicohort, single-arm phase 2 trial.

Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A. Lancet Oncol. 2016 Sep;17(9):1283-94. http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30167-X/fulltext